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Abstract: We describe maleic-acid derivatives as robust
cysteine-selective reagents for protein labelling with compara-
ble kinetics and superior stability relative to maleimides.
Diamide and amido-ester derivatives proved to be efficient
protein-labelling species with a common mechanism in which
a spontaneous cyclization occurs upon addition to cysteine.
Introduction of chlorine atoms in their structures triggers ring
hydrolysis or further conjugation with adjacent residues, which
results in conjugates that are completely resistant to retro-
Michael reactions in the presence of biological thiols and
human plasma. By controlling the microenvironment of the
reactive site, we can control selectivity towards the hydrolytic
pathway, forming homogeneous conjugates. The method is
applicable to several scaffolds and enables conjugation of
different payloads. The synthetic accessibility of these reagents
and the mild conditions required for fast and complete
conjugation together with the superior stability of the con-
jugates make this strategy an important alternative to male-
imides in bioconjugation.
Introduction
Over the last decade protein site-selective conjugation has
become a thriving research field.[1] A plethora of methods
have been reported for the construction of protein conjugates
with a wide array of applications in chemical biology and
medicine.[2] Cysteine[3] (Cys) and lysine[4] (Lys) remain the
main target residues in protein modification although re-
cently, methodologies that target alternative residues, such as
aspartic/glutamic acid,[5] tryptophan,[6] methionine,[7] serine,[8]
or tyrosine,[9] have been described. Cys-targeting methods are
particularly ubiquitous, as they yield structurally homoge-
neous conjugates in proteins that contain native[10] or
genetically engineered free Cys.[11] Multiple strategies have
been reported for Cys-selective conjugation, usually based on
alkylation[12]/arylation[13] reagents or Michael acceptors.[14]
Michael acceptors, particularly maleimides, remain the most
commonly used reagent for the construction of conjugates for
biological applications[15] because of their associated fast
reaction kinetics. In fact, a number of Food and Drug
Administration-approved conjugates, such as antibody–drug
conjugates (ADCs) Brentuximab vedotin[15] and Trastuzumab
emtansine[16] or PEGylated conjugate Certolizumab pegol,[17]
contain a thio-succinimide adduct derived from maleimide
conjugation.[18]
However, it is well known that thio-succinimide adducts
can undergo fast and uncontrolled disruptive cleavage by
thiol-exchange in plasma, which ultimately compromises the
safety and efficacy of the conjugate.[19] Considerable efforts
have been reported on how to increase the stability of
maleimide-based constructs.[20] The most common approach
consists of hydrolyzing the thio-succinimide linkage to form
a stable, linear thio-succinamic acid species.[21] Different
strategies to control the hydrolysis kinetics have been
described. For instance, the addition of electron-withdrawing
groups in the payload,[22] tuning the amino-acid environment
near the inserted Cys,[21a] or mild ultrasonication[23] can
accelerate thio-succinimide hydrolysis. Alternatively, male-
imides with different leaving groups attached to the vinylic
bond or similar structures have been reported to form
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conjugates with higher stability based on maleimide or
maleamic acid linkages.[24]
There are also acyclic reagents, such as benzoyl acrylic
reagents[11,25] or fumarate derivatives.[26] They produce con-
jugates with linear linkages, which can present enhanced
stability in plasma relative to maleimides.[11, 25] Despite these
advances, most of these strategies fail to combine fast
conjugation kinetics along with the formation of stable
conjugates, which is required for biological applications, and
where maleimides remain the first choice. The challenge
remains to find a general, simple alternative for Cys
bioconjugation with comparable kinetics and synthetic acces-
sibility to maleimides, but complete linkage stability.
We hereby report on diamide and amido ester derivatives
from maleic acid as new, efficient reagents for Cys-selective
protein conjugation. These reagents undergo fast Michael
addition reactions with free Cys-containing proteins in
stoichiometric amounts under physiological conditions. Con-
jugation occurs through an unprecedented mechanism in
which, upon Cys addition, spontaneous cyclization is pro-
moted by attack of an amide moiety to the distal carbonyl
group to form a succinimide link (Scheme 1). By expanding
this approach to 2,3-dichloro butenediamides, we can selec-
tively target free Cys residues that form chloro-maleimide
intermediate linkages, which quickly undergo hydrolysis. The
final conjugates are fully resistant to thiol-exchange and
cleavage in the presence of biological thiols and human
plasma. Through this approach an array of free Cys-contain-
ing proteins could be irreversibly tagged, such as ubiquitin
(Ub), human serum albumin (HSA), or different antibody
fragments, with different tags including azide or alkyne
functionalities. The favorable kinetics, stability, and stoichi-
ometry of the conjugation makes a flexible platform to access
complex constructs, such as ADCs.
Results and Discussion
With the goal of finding alternative approaches to access
homogeneous conjugates with fully stable linkages in free
Cys-containing proteins, we set out to investigate maleic acid
derivatives with labile functionalities, which we envisioned
could undergo fast Michael addition with thiols under
physiological conditions and, upon conjugation, would hydro-
lyze to form succinamic acid structures or equally stable
analogues.
The reactivity of b-mercaptoethanol (BME) was evalu-
ated with different maleic acid derivatives (1–10, Figure 1,
Conditions A, Figures S3–S6) to assess their reactivity as
Michael acceptors. Having determined the reactivity of 1–10
in small molecule experiments, we now exposed these
reagents to the presence of a free Cys-containing protein
(Figure 1, Conditions B, Figures S25–S31). As a model pro-
tein we chose Ub, which was engineered with a reactive Cys at
position 63 (K63C). Surprisingly, the reactivity of the different
species varied depending on the setup. Some species showed
high reactivity in small molecule reactions but no protein
conjugation reactivity, whereas others proved to be very
efficient protein conjugation reagents but were unreactive in
a small molecule setup. In successful conjugations, Cys-
selectivity was confirmed after digestion by MS/MS studies
(Figure S82, S83) and by using EllmanQs reagent as a chemical
control (Figure S32).
Mass analysis of the protein conjugates formed revealed
a unique conjugate with a mass of 8754 Da (protein mass +
188 Da) for all the examples. Interestingly, the mass of the
newly formed conjugate did not correspond to the addition of
Scheme 1. Synthesis of conjugates with linear succinamic acid link-
ages.
Figure 1. Small molecule and Ub reaction with different maleic acid
derivatives. a) Small molecule and protein reaction conditions; b) Con-
versions observed using conditions A or B ; c) Structures of reagents
1—10. DMF= dimethyl formamide.
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the full reagent. Instead, we observed the formation of a thio-
succinimide linkage. The origin of such a linkage is through
intramolecular attack of the amide to the distal carbonyl
group (Scheme 2 a), which can happen prior to or after Cys
conjugation. Similar cyclizations are known although never
triggered by aqueous solution or thiol conjugation.[27] Fur-
thermore, the cyclization step seems to play a key role in the
viability of the conjugation, because only compounds with at
least one secondary amide, capable of driving such a cycliza-
tion, underwent conjugation. To gain better mechanistic
insight, compounds 2, and 5–10 were stirred for 2 h at 25 8C
in DMSO/D2O (NaPi pH 8, 50 mm) to determine if the
cyclization was induced as a result of the pH of the solvent or
the thiol addition. Amido esters 2 and 8 cyclized sponta-
neously in the presence of D2O pH 8 to form a maleimide
species (Figures S1,S2). However, this was not the general
behavior for amido esters; compound 6 together with
diamides 5, 7, 9, and 10 was completely stable under these
conditions. This aqueous stability supports the idea that thiol
addition in the protein environment is responsible for
triggering the cyclization. By using diamide 10 and Ub as
a model, the reaction showed great tolerance for pH [5–9,
Figures S33–S37)] and temperature [25–37 8C (Figures S31
and S36)].
When a reagent with two different secondary amide
groups, such as 9, is conjugated, a regioselectivity issue arises.
The presence of two secondary amide moieties allows for two
possible cyclizations, each driven by one of the amides
(Scheme 2b); each pathway leads to a different conjugate: 9a
or 9 b. The preferred pathway could be controlled by the pH
at which the reaction was done. Under slightly acidic
conditions, pH 6–7, the aryl amide group-directed cyclization
was favored, whereas under basic conditions, pH 8–9, the
opposite selectivity was observed (Figures S38, S39).
Another appealing aspect of this conjugation reaction is
the controlled release of small molecules in a particular
microenvironment of the protein sequence. Upon cyclization,
an amine (diamides) or alcohol (amidoesters) molecule is
released, which could open new approaches for monitoring
reactions (release of fluorophores), Cys-targeted decaging of
payloads or site-directed bifunctionalization of proteins. We
are currently investigating this directed release in our
laboratories and will report it in due course.
The thio-succinimide linkages obtained are known to
hydrolyze over time under physiological conditions to give
a linear and stable N-substituted thio-succinamic acid linkage,
but the kinetics of hydrolysis is extremely slow and often
yields mixtures of conjugates. Harsh hydrolyzing conditions,
such as high pH and temperature, could ultimately lead to the
complete hydrolysis to succinamic acid linkages, but such
conditions are not compatible or desirable with proteins
because they can result in unfolding and loss of functional
properties. To address this problem, we focused on accelerat-
ing the hydrolysis of the linkages created by the conjugation
of maleic acid diamides.
Aqueous instability of dichloro maleimides[24c] suggests
that hydrolysis kinetics of maleimides can be exponentially
increased by the introduction of halogens into the ring. This
led us to think that, by introducing chlorine substituents into
the alkene scaffold of maleic acid diamides, the stability of the
compounds and their reactivity would not be affected,
although now instead of obtaining conjugates with succin-
imide linkages, chloro-maleimide linkages would be gener-
ated, which would quickly hydrolyze to stable linear chloro
maleamic acid species. By following reported procedures[28]
we synthesized symmetrical dichloro butenediamides (11–14,
Figure 2a) and, to our delight, their reactivity still included
a cyclization step which yielded a cyclic chloro-maleimide
linkage with enhanced hydrolysis kinetics. Addition of 11
(3 equiv) to a solution of Ub resulted in complete conjugation
(Figure 2) after 30 min at 25 8C. The cyclic intermediate was
observed if the reaction mixture was analyzed shortly after
addition of the reagent (Figure S71). No trace of cyclic
maleimide linkage and only linear chloro maleic acid linkage
was noted after 30 min at different temperatures (25–37 8C)
and pH [pH 5–9 (Figures S67–S70)], which further supports
the hypothesis of rapid hydrolysis of the linkage. The
mechanism associated with this conjugation is similar to that
of dibromo maleimides[23] in that the linkages obtained are
similar, but an additional cyclization step and much more
favorable hydrolysis kinetics make this approach advanta-
geous to obtain homogeneous, stable maleamic acid linkages.
The generality of the method was demonstrated by
conjugation of 7 and 14 to alternative free Cys-containing
proteins. Under similar conditions, HSA, the N-terminal
domain of phage repressor R434 and a camelian nanobody
targeted at amyloid precursors (HET nanobody)[29] were
effectively conjugated (Figures S40–S42) to 7. In all examples
a Michael addition/cyclization mechanism to yield a succini-
mide was observed, which supports the generality of the
mechanism in different protein sequence microenvironments.
Analysis of the circular dichroism (CD) profiles of the
conjugates relative to native proteins confirmed that overallScheme 2. Regioselectivity of the cyclization step with compound 9.
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the tertiary structure of the proteins was maintained through-
out conjugation (Figures S85, S86).
An array of dichloro butenediamide analogues with
different functionalities were synthesized (compounds 11–
14). Alyphatic 11 and aromatic 12 amide species could be
accessed as well as amides with an incorporated alkyne 13 or
azide 14 functionality. These new functionalities were in-
corporated into the protein structure to enable further
functionalization through copper(I)-catalyzed alkyne–azide
cycloadditon. Compounds 12–14 showed similar reactivity to
11 upon reaction with Ub to form stable, linear chloro-
maleamic acid linkages (Figures S44–S46). However, when
compound 14 was tested with different proteins, upon
conjugation–cyclization, different reactivity was observed
for some of these proteins. In Ub, C2Am[30] or peptide
ASCATN the expected sequential Michael addition–cycliza-
tion–hydrolysis occurs to give a final conjugate with a chloro-
maleamic acid linkage. When the scope is expanded to
proteins like HSA, H3K4C, or the full-length IgG antibody
Gemtuzumab, an alternative pathway consisting of a subse-
quent Michael addition of a proximal nucleophilic residue
occurs, instead of the hydrolysis step (Figure 2 b). This
alternative pathway forms cyclic maleimide linkages with
two residues on the protein. Both linkages cannot undergo
retro-Michael addition and form stable conjugates, which was
demonstrated by analyzing the stability of Ub-14 ; the
conjugate remained stable in buffer, and no degradation
was observed after 48 h at 37 8C in the presence of glutathione
(1 mm) or in human plasma (Figures S73, S74).
The enhanced plasma stability displayed by the conjugates
formed from the reaction of Cys with reagents 11–14 has
potential for the construction of stable ADCs. However,
because two alternative linkages can be formed, this could
constitute an issue regarding homogeneity of the final
construct. Next, we analyzed the ratio between cyclic and
linear conjugates using LCMS. The conjugate derived from
Gemtuzumab V205C showed a mixture of species, [ratio 2:1
cyclic vs. linear (Figure S53)], but all others formed selec-
tively one of the two potential linkages. Conjugation of
HER2-targeted IgG Trastuzumab V205C with 14 led to
a similar result (ratio 4:1, Figure S54).
To explain this result at the atomic level, we performed
molecular dynamics (MD) simulations on the Fab fragment of
Trastuzumab conjugated to compound 14 (Figures 2b and
S87) and examined the distance from all lysine residues to the
reactive carbon (C@Cl). According to these calculations,
lysine at position 207 had the smallest average distance and
was presumably the residue that directed the second nucle-
ophilic attack to form the cyclic derivative. The simulations
indicated also that the incorporation of this cyclic derivative
into Fab does not significantly disrupt its structure (Fig-
ure 2b). The involvement of K207 in the formation of the
cyclic linkage was further confirmed by MS/MS studies on
Trastuzamab V205C-14 (Figure S84). By mutating lysine 207
into an alanine, the new Trastuzumab V205C + K207A was
conjugated to 14 and this time complete selectivity to the
linear linkage was obtained (Figure S55). This result support-
ed the idea that nearby lysine residues were the driving
factors for the formation of the cyclic linkage, allowing us to
predict the final linkage formed and if mixtures were to arise,
avoid the formation of the cyclic species by introducing
cysteines in the appropriate place or mutating the problem-
atic lysine residues. We found, however, that mutation of
lysine 207 in Trastuzumab V205 + K207A reduces the nucle-
ophilicity of cysteine 205 and only approx. 50% conjugation is
achieved under the previously described conditions (Fig-
ure S55).
To find suitable positions to genetically encode a reactive
Cys that allow complete conversion, yet selective formation
of the stable linear linkage, we produced Fc fragments of an
IgG with Cys insertions at different positions (239iC, 268C,
274C, 289C and 442C). Under identical reaction conditions
with 14, the Fc fragments with 274C and 289C reacted
completely and selectively formed the linear linkage (Figur-
es S56–S60). These simple maleic acid derivatives enable
installation of modifications on antibodies at specific sites to
form homogeneous and stable antibody conjugates.
To compare the kinetics of conjugation between maleic
acids and maleimides, an equimolar mixture of 11 and its
Figure 2. a) Conjugation reaction of reagents 11–14 with different Cys-
containing proteins. b) Representative snapshot derived from 0.5 ms
MD simulations on conjugate HER2-14. The RMSD value of the
protein, relative to the first frame, is also shown. c) Conjugation
reaction of Trastuzumab V205C, K207A with 14. d) Conjugation
reaction of Fc fragments 274C and 289C with 14.
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analogous maleimide reagent were conjugated to Fc fragment
289iC. Under the same conditions, 11 and maleimide showed
comparable conjugation kinetics as a 1:1 mixture of Fc-11 and
Fc-maleimide constructs was obtained (Figure S81). How-
ever, when we compared the stability of the constructs in the
presence of GSH (1 mm) after 66 h at 37 8C, the constructs
(trastuzumab-11, Fc 274iC-11, Fc 289iC-11) conjugated to 11
showed higher stability than the corresponding species
conjugated with maleimide (Figures S75–S80). While the
conjugates formed with reagent 11 remain intact in the
presence of a thiol, constructs built using maleimides form
a mixture of hydrolyzed maleimide and unconjugated anti-
body. These data show a key advantage of our reagents to
build stable conjugates and illustrate how enhanced hydroly-
sis kinetics of the cyclic linkages allows the formation of fully
stable species.
Conclusion
We describe the protein conjugation reactivity of a series
of maleic acid derivatives and identify amido esters and
diamides as viable conjugation reagents to produce succin-
imide linkages through a new stepwise mechanism. The
strategy was optimized to use dichloro butenediamides, which
promote a further hydrolysis step to form completely stable
linkages to proteins. This latter species shows comparable
conjugation kinetics relative to maleimides yet benefits from
superior stability. The general mechanism described com-
poses a Michael addition followed by spontaneous cyclization
to form cyclic linkages similar to those obtained by conjuga-
tion to maleimides. Introduction of Cl atoms into the cyclic
linkages promotes subsequent hydrolysis, leading to fully
stable linkages. Nearby nucleophilic residues can promote an
alternative mechanism where a second nucleophilic attack
leads to the formation of a cyclic linkage, but this pathway can
be controlled and depleted if undesired conjugate mixtures
are obtained. The approach allows for the creation of
conjugates with azide/alkyne moieties and opens up possibil-
ities to create tailored conjugation for a number of relevant
proteins, including nanobodies or IgGs relevant for the
formation of ADCs.
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